Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
454.44
+13.72 (+3.11%)
4:43:07 PM EDT: $454.49 +0.05 (+0.01%)
Products, Regulatory

EMA Approves Increase In Biontech/Pfizer And Moderna COVID-19 Vaccine Making Capacity

Published: 08/24/2021 12:43 GMT
Moderna Inc (MRNA) - Ema: Ema: Increase in Vaccine Manufacturing Capacity for Covid-19 Vaccines From Biontech / Pfizer and Moderna.
Ema Says Ema's Human Medicines Committee (chmp) Has Adopted Recommendations That Will Increase Manufacturing Capacity and Supply of Covid-19 Vaccines in Eu.
Ema: Saint Remy Sur Avre, France Site Will Allow to Provide Approximately Up to 51 Million Additional Doses of Pfizer Shot in 2021.
Ema: Chmp Has Also Approved an Additional Manufacturing Site for the Production of Spikevax, the Covid-19 Vaccine Developed by Moderna.
Ema Says Has Also Approved a New Manufacturing Line at Biontech's Manufacturing Site in Marburg, Germany.
Ema Says Chmp Has Also Approved an Additional Manufacturing Site for Production of Spikevax, Covid-19 Vaccine Developed by Moderna.
Ema -chmp Has Also Approved Several Alternative Sites Responsible for Batch Control/testing and Packaging of Finished Product Manufactured by Catalent.
Ema Says Recommendations Do Not Require a European Commission Decision and Sites Can Become Operational Immediately.
Ema: Approved New Manufacturing Line at Biontech's Manufacturing Site in Marburg, Which Increases Active Substance Manufacturing Capacity by About 410 Mln Doses in 2021.
((reuters.
Briefs@thomsonreuters.
Com;)).